AI-generated analysis. Always verify with the original filing.
Phio Pharmaceuticals Corp. reported 2025 year-end financial results with net loss of $8.7 million and cash of $21.0 million at December 31, 2025, up from $5.4 million prior year, after $23.7 million in net proceeds from financings extending cash runway into first half of 2027. Phase 1b trial for PH-762 completed dose escalation with favorable safety data; FDA submission targeted for Q2 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
and attached as Exhibit 99.1 to this Report will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (th
. Financial Statements and Exhibits. (d) Exhibits. Number Description 99.1 Press release issued by the Company on March 5, 2026 104 Cover Page Interactive Data
| Metric | Value | Basis |
|---|---|---|
| Research and Development Expenses | $4.6K | GAAP |
| General and Administrative Expenses | $4.6K | GAAP |
| Total Operating Expenses | $9.2K | GAAP |
| Operating Loss | $9.2K | GAAP |
| Net Loss | $8.7K | GAAP |
| Net Loss per Common Share | $-1.45 | GAAP |